- Home
- OMER vs BBOT Comparison
OMER vs BBOT Comparison
Compare OMER & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMER | BBOT |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 844.6M | 717.8M |
| IPO Year | 2008 | 2024 |
Fundamental Metrics
Financial Performance| Metric | OMER | BBOT |
|---|---|---|
| Price | $17.33 | $9.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $32.50 | $24.00 |
| AVG Volume (30 Days) | ★ 2.0M | 249.7K |
| Earning Date | 05-14-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 98.15 | ★ 99.93 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $29,868,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $233.22 | N/A |
| P/E Ratio | $22.49 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.94 | $7.00 |
| 52 Week High | $18.14 | $14.87 |
Technical Indicators
Market Signals| Indicator | OMER | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 83.27 | 55.71 |
| Support Level | $9.12 | $7.99 |
| Resistance Level | $17.65 | $9.45 |
| Average True Range (ATR) | 0.75 | 0.49 |
| MACD | 0.52 | 0.04 |
| Stochastic Oscillator | 87.76 | 67.90 |
Price Performance
Historical ComparisonAbout OMER Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
About BBOT BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.